ANALIZE MEDICALE DE LABORATOR
            Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
            Selectati o categorie din lista de mai jos:
            
         
     
    
    
    
        Solutie antistress!
 Construieste poduri :)
         Prinde pisica neagra :)
        
        Prinde pisica neagra :)
         
     
 
Quintiles Data Management Surpasses 300 EDC Trials
Quintiles 
Transnational Corp. announced it has achieved another major milestone 
in the management of clinical trial data -- 300 clinical trials using 
Electronic Data Capture (EDC).
     
The milestone EDC trial is a Phase II study being conducted for Pacgen   
Biopharmaceuticals Corporation of Vancouver, British Columbia. Pacgen is 
studying an anti-infective drug for the treatment of oral candidiasis. 
Quintiles began using EDC in 1999 and has seen acceptance of the technology 
accelerate since then, with more than 94 EDC trials put into production in 
2007.
 
    
"At Quintiles, EDC is quickly surpassing paper in the collection of   
clinical trial data as customers are placing increased value on our ability 
to give them expert guidance in the appropriate use of this technology, as 
well as the potential for savings in time and cost," said Paula Brown 
Stafford, Executive Vice President, Global Data Management and 
Biostatistics, and a member of the CDISC Board of Directors. "We have been 
able to demonstrate for the pharmaceutical and biotech industries that EDC, 
when used properly, can make much better use of available resources.
 
    
"With Pacgen, we're working with an emerging biopharmaceutical company  
that is conducting important research in infectious diseases," she added. 
"Quintiles looks forward to continuing to help Pacgen further develop its 
pipeline."
 
    
About Pacgen
    
Pacgen is a life sciences company focused on the development of 
therapeutics for the treatment of infectious and inflammatory diseases. The 
company's lead product, PAC-113, is an anti-fungal in a Phase II clinical  
program. Pacgen also has candidates in an early stage research program. The 
most advanced of these candidates is a novel peptide therapeutic, PAC-G31P,  
which is currently being investigated in preclinical studies for its 
potential to treat inflammatory diseases characterized by non-beneficial 
neutrophil recruitment and activation.
 
    
About Quintiles
    
Quintiles Transnational Corp. is powering the next generation of 
healthcare by providing a broad range of professional services in drug 
development, financial partnering and commercialization for the 
pharmaceutical, biotechnology and healthcare industries. With more than  
19,000 employees and offices in more than 50 countries, it is focused on 
providing customer-centric solutions that are the gold standard of the 
industry. For more information, please visit the company's Web site at 
http://www.quintiles.com.
 
Quintiles Transnational Corp.
http://www.quintiles.com
		
Chintile de management de date depãºeºte 300 EDC studii clinice - Quintiles Data Management Surpasses 300 EDC Trials - articole medicale engleza - startsanatate